{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:08:38Z","timestamp":1791724118727,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03113-5","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:40:10Z","timestamp":1762591210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Empagliflozin mitigates doxorubicin-induced hepatotoxicity by reducing inflammation, oxidative stress, and apoptosis in male NMRI mice"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0139-066X","authenticated-orcid":false,"given":"Nafiseh","family":"Asgari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1530-5357","authenticated-orcid":false,"given":"Zahra","family":"Kalhori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"1","key":"3113_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-pharmtox-030620-104842","volume":"61","author":"KT Sawicki","year":"2021","unstructured":"Sawicki KT, Sala V, Prever L, Hirsch E, Ardehali H, Ghigo A. Preventing and treating anthracycline cardiotoxicity: new insights. Annu Rev Pharmacol Toxicol. 2021;61(1):309\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3113_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00210-021-02119-w","volume":"394","author":"M Shokrzadeh","year":"2021","unstructured":"Shokrzadeh M, Bagheri A, Ghassemi-Barghi N, Rahmanian N, Eskandani M. Doxorubicin and doxorubicin-loaded nanoliposome induce senescence by enhancing oxidative stress, hepatotoxicity, and in vivo genotoxicity in male Wistar rats. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. 2021;394:1803\u201313.","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"2","key":"3113_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229.","journal-title":"Pharmacol Rev"},{"issue":"12","key":"3113_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","volume":"11","author":"KA Sauter","year":"2011","unstructured":"Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1\u03b2 through activation of the NLRP3 inflammasome: progress at a snail\u2019s pace. Cancer Biol Ther. 2011;11(12):1008\u201316.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"3113_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853\u20138.","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"3113_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0026-895X(25)10149-1","volume":"45","author":"FA Fornari","year":"1994","unstructured":"Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45(4):649\u201356.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3113_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/biom12010143","volume":"12","author":"C Llorens-Cebri\u00e0","year":"2022","unstructured":"Llorens-Cebri\u00e0 C, Molina-Van den Bosch M, Vergara A, Jacobs-Cach\u00e1 C, Soler MJ. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules. 2022;12(1):143.","journal-title":"Biomolecules"},{"issue":"1","key":"3113_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00951-5","volume":"14","author":"S Gohari","year":"2022","unstructured":"Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, et al. The effect of empagliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and coronary artery disease: the EMPA-CARD randomized controlled trial. Diabetol Metab Syndr. 2022;14(1):170.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"3113_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1197061","volume":"2022","author":"M Ala","year":"2022","unstructured":"Ala M, Khoshdel MRF, Dehpour AR. Empagliflozin enhances autophagy, mitochondrial biogenesis, and antioxidant defense and ameliorates renal ischemia\/reperfusion in nondiabetic rats. Oxid Med Cell Longev. 2022;2022(1):1197061.","journal-title":"Oxid Med Cell Longev"},{"key":"3113_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.944886","volume":"13","author":"Y Ma","year":"2022","unstructured":"Ma Y, Zhang G, Kuang Z, Xu Q, Ye T, Li X, et al. Empagliflozin activates Sestrin2-mediated AMPK\/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease. Front Pharmacol. 2022;13:944886.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3113_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112152","volume":"11","author":"MA ElBaset","year":"2022","unstructured":"ElBaset MA, Salem RS, Ayman F, Ayman N, Shaban N, Afifi SM, et al. Effect of empagliflozin on thioacetamide-induced liver injury in rats: role of AMPK\/SIRT-1\/HIF-1\u03b1 pathway in halting liver fibrosis. Antioxidants. 2022;11(11):2152.","journal-title":"Antioxidants"},{"issue":"2","key":"3113_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxres\/tfad007","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis. Toxicol Res. 2023;12(2):216\u201323.","journal-title":"Toxicol Res"},{"issue":"2","key":"3113_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.30699\/ijbd.16.2.67","volume":"16","author":"M Moghiseh","year":"2023","unstructured":"Moghiseh M, Mirzayan SS, Banaifar AA, Kazemzadeh Y. The effect of aerobic exercise training and micelles on the consumption of Curcumin nano expression level of CASP3, CASP9, Bax and BCL2 with genes on cardiac tissues of Balb\/C mice induced breast cancer treated with doxorubicin. Iran J Breast Dis. 2023;16(2):67\u201383.","journal-title":"Iran J Breast Dis"},{"issue":"2","key":"3113_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","volume":"65","author":"M Kern","year":"2016","unstructured":"Kern M, Kl\u00f6ting N, Mark M, Mayoux E, Klein T, Bl\u00fcher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65(2):114\u201323.","journal-title":"Metabolism"},{"issue":"7","key":"3113_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2022.103308","volume":"29","author":"DO Saleh","year":"2022","unstructured":"Saleh DO, Mahmoud SS, Hassan A, Sanad EF. Doxorubicin-induced hepatic toxicity in rats: mechanistic protective role of omega-3 fatty acids through Nrf2\/HO-1 activation and PI3K\/Akt\/GSK-3\u03b2 axis modulation. Saudi J Biol Sci. 2022;29(7):103308.","journal-title":"Saudi J Biol Sci"},{"key":"3113_CR16","doi-asserted-by":"publisher","first-page":"S1121","DOI":"10.14309\/01.ajg.0000784228.17250.65","volume":"116","author":"Y Hegazy","year":"2021","unstructured":"Hegazy Y, Turner M, Fettig D. S2674 a subtle case of doxorubicin-induced hepatotoxicity. Am J Gastroenterol. 2021;116:S1121.","journal-title":"Am J Gastroenterol"},{"issue":"21","key":"3113_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115525","volume":"24","author":"KS El-Said","year":"2023","unstructured":"El-Said KS, Haidyrah AS, Mobasher MA, Khayyat AIA, Shakoori A, Al-Sowayan NS, et al. Artemisia annua extract attenuate doxorubicin-induced hepatic injury via PI-3K\/Akt\/Nrf-2-mediated signaling pathway in rats. Int J Mol Sci. 2023;24(21):15525.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3113_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1):150.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"3113_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10121998","volume":"10","author":"AF AlAsmari","year":"2021","unstructured":"AlAsmari AF, Alharbi M, Alqahtani F, Alasmari F, AlSwayyed M, Alzarea SI, et al. Diosmin alleviates doxorubicin-induced liver injury via modulation of oxidative stress-mediated hepatic inflammation and apoptosis via NfkB and MAPK pathway: a preclinical study. Antioxidants. 2021;10(12):1998.","journal-title":"Antioxidants"},{"key":"3113_CR20","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","volume":"61","author":"N Sattar","year":"2018","unstructured":"Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial. Diabetologia. 2018;61:2155\u201363.","journal-title":"Diabetologia"},{"issue":"7","key":"3113_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073668","volume":"23","author":"L Mirarchi","year":"2022","unstructured":"Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 inhibitors as the most promising influencers on the outcome of non-alcoholic fatty liver disease. Int J Mol Sci. 2022;23(7):3668.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3113_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063107","volume":"23","author":"T Androutsakos","year":"2022","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis A-D, Kyrou I, Efstathopoulos E, Randeva HS, et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022;23(6):3107.","journal-title":"Int J Mol Sci"},{"key":"3113_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154883","volume":"116","author":"W Gao","year":"2023","unstructured":"Gao W, Zhao Y, Guo L, Wang Y, Gong H, Zhang B, et al. Comparative effectiveness of glycyrrhizic acid preparations aimed at improving liver function of patients with chronic hepatitis B: a network meta-analysis of 53 randomized controlled trials. Phytomedicine. 2023;116:154883.","journal-title":"Phytomedicine"},{"issue":"1","key":"3113_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.3922","volume":"42","author":"N Safaie","year":"2024","unstructured":"Safaie N, Masoumi S, Alizadeh S, Mirzajanzadeh P, Nejabati HR, Hajiabbasi M, et al. SGLT2 inhibitors and AMPK: the road to cellular housekeeping? Cell Biochem Funct. 2024;42(1):e3922.","journal-title":"Cell Biochem Funct"},{"issue":"4","key":"3113_CR25","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.13005\/bpj\/2787","volume":"16","author":"A Khwaldeh","year":"2023","unstructured":"Khwaldeh A, Al-Sawalha N, Shraideh Z, Ababneh S, Bdeir R, Empagliflozin. Potential protective effects on hepatocytes and liver outcomes in Streptozotocin-Diabetic rats. Biomed Pharmacol J. 2023;16(4):2123\u201333.","journal-title":"Biomed Pharmacol J"},{"key":"3113_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","volume":"588","author":"N Lee","year":"2022","unstructured":"Lee N, Heo YJ, Choi S-E, Jeon JY, Han SJ, Kim DJ, et al. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochem Biophys Res Commun. 2022;588:154\u201360.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"3113_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094054","volume":"26","author":"YJ Heo","year":"2025","unstructured":"Heo YJ, Park J, Lee N, Choi S-E, Jeon JY, Han SJ, et al. Empagliflozin alleviates hepatic steatosis and oxidative stress via the NRF1 pathway in high-fat diet-induced mouse model of metabolic dysfunction-associated steatotic liver disease. Int J Mol Sci. 2025;26(9):4054.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3113_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/dom.12982","volume":"19","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19(10):1353\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3113_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.arcmed.2007.01.007","volume":"38","author":"M Yagmurca","year":"2007","unstructured":"Yagmurca M, Bas O, Mollaoglu H, Sahin O, Nacar A, Karaman O, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res. 2007;38(4):380\u20135.","journal-title":"Arch Med Res"},{"issue":"1","key":"3113_CR30","first-page":"606183","volume":"2012","author":"J Dudka","year":"2012","unstructured":"Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, et al. Different effects of Resveratrol on dose-related doxorubicin\u2010induced heart and liver toxicity. Evid Based Complement Alternat Med. 2012;2012(1):606183.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3113_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","volume":"293","author":"M Pecoraro","year":"2016","unstructured":"Pecoraro M, Del Pizzo M, Marzocco S, Sorrentino R, Ciccarelli M, Iaccarino G, et al. Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol. 2016;293:44\u201352.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3113_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 Inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:1\u201313.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"3113_CR33","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kovacs A, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690\u2013700.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"3113_CR34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213\u201325.","journal-title":"J Mol Cell Cardiol"},{"key":"3113_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20:1\u201320.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"3113_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050799","volume":"11","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ding Y, Sun P, Zhang W, Xin Q, Wang N, et al. Empagliflozin-enhanced antioxidant defense attenuates lipotoxicity and protects hepatocytes by promoting FoxO3a-and Nrf2-mediated nuclear translocation via the CAMKK2\/AMPK pathway. Antioxidants. 2022;11(5):799.","journal-title":"Antioxidants"},{"issue":"13","key":"3113_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137477","volume":"25","author":"R Vitale","year":"2024","unstructured":"Vitale R, Marzocco S, Popolo A. Role of oxidative stress and inflammation in doxorubicin-induced cardiotoxicity: a brief account. Int J Mol Sci. 2024;25(13):7477.","journal-title":"Int J Mol Sci"},{"key":"3113_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cbi.2014.01.013","volume":"212","author":"B Wang","year":"2014","unstructured":"Wang B, Ma Y, Kong X, Ding X, Gu H, Chu T. NAD+ administration decreases doxorubicin-induced liver damage of mice by enhancing antioxidation capacity and decreasing DNA damage. Chemico-Biological Interactions. 2014;212:65\u201371.","journal-title":"Chemico-Biological Interactions"},{"issue":"1","key":"3113_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-024-00669-3","volume":"10","author":"AA Mishriki","year":"2024","unstructured":"Mishriki AA, Khalifa AK, Ibrahim DA, Hashem GMAZ, Rashed LA, Abdelrahman SS, et al. Empagliflozin mitigates methotrexate-induced nephrotoxicity in male albino rats: insights on the crosstalk of AMPK\/Nrf2 signaling pathway. Future J Pharm Sci. 2024;10(1):95.","journal-title":"Future J Pharm Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03113-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:02:15Z","timestamp":1763827335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03113-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3113"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03113-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were approved by the Ethics Committee of Razi University of Kermanshah (IR.RAZI.REC.1402.069).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"542"}}